Related Experiment Video
Updated: Jul 25, 2025
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Long-Term Follow-Up of Pediatric Patients with Dyskinetic Cerebral Palsy and Deep Brain Stimulation
Anne Koy1, Andrea A Kühn2, Petra Schiller3
1Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Insights
Deep brain stimulation (DBS) significantly improved dyskinesia in pediatric patients with dyskinetic cerebral palsy (DCP). Long-term safety and efficacy require further investigation in larger studies.
Area of Science:
- Neurology
- Pediatric Medicine
- Neurosurgery
Background:
- Deep brain stimulation (DBS) is increasingly utilized for managing dyskinetic cerebral palsy (DCP).
- Limited data exist on the long-term effects and safety profile of DBS in this population.
Purpose of the Study:
- To evaluate the efficacy and safety of pallidal DBS in pediatric patients diagnosed with DCP.
- To assess motor and non-motor outcomes following DBS treatment.
Main Methods:
- Prospective, single-arm, multicenter STIM-CP trial.
- Follow-up of patients for up to 36 months.
- Inclusion of 14 pediatric patients with DCP (mean age 14 years).
Main Results:
- Significant improvement in the Dyskinesia Impairment Scale at 36 months.
- Twelve serious adverse events potentially related to treatment were recorded.
- No significant changes observed in other outcome parameters.
Conclusions:
- Pallidal DBS demonstrates significant efficacy in improving dyskinesia in pediatric DCP.
- Further research with larger, homogeneous cohorts is necessary to confirm these findings and guide treatment.
- Long-term impact and optimal patient selection for DBS in DCP warrant continued investigation.
Background:
Deep brain stimulation (DBS) has been increasingly used in the management of dyskinetic cerebral palsy (DCP). Data on long-term effects and the safety profile are rare.
Objectives:
We assessed the efficacy and safety of pallidal DBS in pediatric patients with DCP.
Methods:
The STIM-CP trial was a prospective, single-arm, multicenter study in which patients from the parental trial agreed to be followed-up for up to 36 months. Assessments included motor and non-motor domains.
Results:
Of the 16 patients included initially, 14 (mean inclusion age 14 years) were assessed. There was a significant change in the (blinded) ratings of the total Dyskinesia Impairment Scale at 36 months. Twelve serious adverse events (possibly) related to treatment were documented.
Conclusion:
DBS significantly improved dyskinesia, but other outcome parameters did not change significantly. Investigations of larger homogeneous cohorts are needed to further ascertain the impact of DBS and guide treatment decisions in DCP. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
